Ovarian cancer is one of the most challenging malignancies in oncology. Despite advances in diagnosis and treatment, it is ...

AbbVie is investing $195m to strengthen domestic API production, with the expansion of its manufacturing plant in North ...

Our editorial team dives into the pharma industry's reaction to US tariffs on imports from the European Union and major trends from Q2 earnings calls.

South Korea’s pharma industry has a valuable pool of promising drugs, but China still leads the way in out-licensing deals.

PharmaTher's ketamine product is the first to be approved in an analgesic setting by the FDA, offering competition to opiates moving forward.

Sartorius has agreed to invest $3m in Nanotein Technologies, engaged in the development of advanced immune cell activation reagents.

Fosun Pharma Industrial has entered a licence agreement to grant ex-China rights for its respiratory drug, XH-S004, to Expedition.

WeightWatchers is now only offering Wegovy while other telehealth providers defiantly hang on to compounded alternatives.

This will be the first time the option has been taken up since it was introduced at the beginning of 2025, under the Medical Research Act.

As tariffs on drug imports from the EU look set to alter pricing and manufacturing strategies, each entity needs to study its full impact.

Denny Bros will be attending London Packaging Week 2025 on the 15th and 16th of October, and their booth number is C84.

Biostar Stem Cell Technology Research Institute has received Japan's MHLW approval for its angel stem cell therapy for ASD.